Results 101 to 110 of about 42,056 (305)
CD47‐SIRPα axis is an immunotherapeutic target in tumor therapy. However, current monoclonal antibody targeting CD47‐SIRPα axis is associated with on‐target off‐tumor and antigen sink effects, which significantly limit its potential clinical application.
Jinfeng Gao +17 more
semanticscholar +1 more source
Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu +8 more
wiley +1 more source
Of macrophages and red blood cells; a complex love story [PDF]
Macrophages tightly control the production and clearance of red blood cells (RBC). During steady state hematopoiesis, approximately 10(10) RBC are produced per hour within erythroblastic islands in humans.
Djuna Z. de Back +4 more
core +2 more sources
Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis
Background The dynamic interaction between cancer cells and tumour-associated macrophages (TAMs) in the hypoxic tumour microenvironment (TME) is an active barrier to the effector arm of the antitumour immune response.
Xiaojing Chen +9 more
semanticscholar +1 more source
CD47-Blocking Antibodies and Atherosclerosis
Phagocytosis is a well understood process whereby pathogens and cell debris are removed from within the body, and it is an important homeostatic mechanism in health and disease. What is less commonly discussed is the process of “efferocytosis.” This term, derived from the Latin prefix effero- ,
openaire +3 more sources
Targeting CD47 in Sézary syndrome with SIRPαFc
AbstractSézary syndrome (SS), the leukemic variant of cutaneous T-cell lymphoma, has limited treatment options and rare occurrences of long-term remission, thus warranting research into new treatment approaches. CD47 has emerged as a promising target for multiple tumor types, but its role in SS remains unknown.
Lisa D. S. Johnson +16 more
openaire +2 more sources
The effects of obesity on CD47 expression in erythrocytes [PDF]
BackgroundTo investigate the effects of obesity on CD47, phosphatidylserine (PS) exposure, and Caspase‐8 and Caspase‐3 activities in erythrocytes.MethodsThe study included 25 morbidly obese patients and 20 healthy people as the control group. We evaluated CD47 expression on the red blood cell (RBC) membrane surface and eryptosis markers such as PS ...
Maciej, Wiewiora +4 more
openaire +2 more sources
Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4‐Mediated Acute Hepatitis
This study identifies hepatocyte‐derived BDNF as an endogenous TLR4 antagonist that alleviates acute hepatitis. BDNF is downregulated in hepatocytes via REST‐mediated transcriptional repression during ALI/ALF. Mechanistically, BDNF binds to TLR4 on macrophages to suppress inflammation.
Weiwei Zhu +15 more
wiley +1 more source
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages [PDF]
We have read with great interest the recent article of Kohrt, H.E. et al1 showing that Ibrutinib prevented NK cell mediated cytotoxicity of antibody-coated CLL cells in vitro.
Almejún, María Belén +8 more
core +2 more sources
sEVs‐circ6718 serves as a promising serum biomarker for gastric cancer early diagnosis and prognosis, promoting malignant transformation in gastric cancer cells and GC‑MSC differentiation into CAFs. sEVs‑circ6718 holds potential as a biomarker for the early diagnosis and prognostic assessment of gastric cancer.
Fan Zhang +7 more
wiley +1 more source

